The discovery of non-benzimidazole and brain-penetrant prolylcarboxypeptidase inhibitors
作者:Thomas H. Graham、Hong C. Shen、Wensheng Liu、Yusheng Xiong、Andreas Verras、Kelly Bleasby、Urmi R. Bhatt、Renee M. Chabin、Dunlu Chen、Qing Chen、Margarita Garcia-Calvo、Wayne M. Geissler、Huaibing He、Michael E. Lassman、Zhu Shen、Xinchun Tong、Elaine C. Tung、Dan Xie、Suoyu Xu、Steven L. Colletti、James R. Tata、Jeffrey J. Hale、Shirly Pinto、Dong-Ming Shen
DOI:10.1016/j.bmcl.2011.10.060
日期:2012.1
Novel prolylcarboxypeptidase (PrCP) inhibitors with nanomolar IC50 values were prepared by replacing the previously described dichlorobenzimidazole-substituted pyrrolidine amides with a variety of substituted benzylamine amides. In contrast to prior series, the compounds demonstrated minimal inhibition shift in whole serum and minimal recognition by P-glycoprotein (P-gp) efflux transporters. The compounds were also cell permeable and demonstrated in vivo brain exposure. The in vivo effect of compound (S)-6e on weight loss in an established diet-induced obesity (eDIO) mouse model was studied. (C) 2011 Elsevier Ltd. All rights reserved.